Re-purposing cancer therapeutics for breast cancer immunotherapy

Cancer Immunology, Immunotherapy

Volumn 61, Issue 8, 2012, Pages 1299-1305

  Emens, Leisha A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Breast cancer; Chemotherapy; Cyclophosphamide; Immunotherapy; Monoclonal antibody; PIVAC 11

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7 16 4; MONOCLONAL ANTIBODY DC101; PACLITAXEL; TRASTUZUMAB; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANTIBODY RESPONSE; BREAST CANCER; CANCER IMMUNOTHERAPY; DISEASE MODEL; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR REJECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CONGRESSES AS TOPIC; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOTHERAPY; RECEPTOR, ERBB-2;

EID: 84865803534     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1247-z     Document Type: Review

References (30)

1. KantoV P, Higano C, Shore N, Berger E, Small E et al (2010) Sipuleucel- T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422
2. Hodi F, O'Day S, McDermott D, Weber R, Sosman J et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
3. Robert C, Thomas L, Bondarenko I, O'Day S et al (2011) Ipilimumab plus decarbazine for previously untreated melanoma. N Engl J Med 364:2517-2526
4. Emens L, JaVee E (2007) Immunotherapy and cancer therapeutics: why partner? In: Prendergast G, JaVee E (eds) Cancer immunotherapy and immune suppression, 1st edn. Academic Press, Elsevier, London, pp 207-233
5. Emens L (2010) Chemoimmunotherapy. Cancer J J Princ Prac Oncol 16:295-303
6. Emens L, Machiels J, Reilly R, JaVee E (2001) Chemotherapy: friend or foe to cancer vaccines? Curr Opin Mol Ther 3:77-84
7. Ferris R, JaVee E, Ferrone S (2010) Tumor-Antigen-Targeted, monoclonal antibody0based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 28:4390-4399
8. Guy CT, Webster MA, Schaller M, Parsons TJ, CardiV RD et al (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89:10578-10582
9. Reilly RT, Gattlieb MB, Ercolini AM, Machiels JP, Kane CE et al (2000) HER-2/neu is a tumor rejection target in tolerized HER-2/ neu transgenic mice. Cancer Res 60:3569-3576 (Pubitemid 30482178)
10. Machiels J, Reilly R, Emens L, Ercolini A, Lei R et al (2001) Cyclophospha-mide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689-3697 (Pubitemid 32694981)
11. Ercolini A, Machiels J, Chen Y, Slansky J, Giedlen M et al (2003) IdentiWcation and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-Transgenic mice. J Immunol 170:4273-4280 (Pubitemid 36428195)
12. Uram J, Black C, Flynn E, Huang L, Armstrong T et al (2011) Nondominant CD8+ T cells are active players in the vaccineinduced antitumor immune response. J Immunol 186:3847-3857
13. Nigam A, Yacavone R, Zahurak M, Johns C, Pardoll D et al (1998) Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Cancer 12:161-170 (Pubitemid 28027242)
14. Ercolini A, Ladle B, Manning E, Pfannenstiel L, Armstrong T et al (2005) Recruitment of latent pools of high-Avidity CD8+ T cells to the antitumor immune response. J Exp Med 201:1519-1602
15. Reilly R, Machiels J, Emens L, Ercolini A, Okoye F et al (2001) The collaboration of both humoral and cellular HER-2/neu-Targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 61:880-883 (Pubitemid 32174395)
16. Wolpoe M, Lutz E, Murata S, Ivie S et al (2003) HER-2/neu-speciWc monoclonal antibodies collaborate with HER-2/neu-Targeted granulocyte macrophage colony-stimulating whole cell vaccination to augment CD8+ T cell eVector function and tumor-free survival in HER-2/neu-Transgenic mice. J Immunol 171:2161-2169 (Pubitemid 36966500)
17. Kim P, Armstrong T, Song H, Wolpoe M, Weiss V et al (2008) Antibody association with HER-2/neu-Targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs. J Clin Investig 188:1700-1711 (Pubitemid 351632374)
18. Davis-Sproul JM, Harris MP, Davidson NE, Kobrin BJ, JaVee EM et al (2005) Cost-eVective manufacture of an allogenic GM-CSFsecreting breast tumor vaccine in an academic cGMP facility. Cytotherapy 7:46-56 (Pubitemid 40542403)
19. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, WolV AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, JaVee EM (2009) Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colonystimulating factor-secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27:5911-5918
20. Emens L, Gupta R, Petrik S, Laiko M, Levi J et al (2011) A feasibility study of combination therapy with trastuzumab (T), cyclophoshamide (CY), and al allogenic GM-CSF-secreting breast tumor vaccine for the treatment of HER-2+ breast cancer. Proc Am Soc Clin Oncol (abstract 2435
21. Emens LA (2005) Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 12:243-253 (Pubitemid 40825130)
22. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S et al (1999) Multinational study of the eYcacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progress after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648 (Pubitemid 29415219)
23. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN et al (2002) EYciacy and safety of trastuzumab as a single agent in the Wrst-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726 (Pubitemid 34111379)
24. Clynes R, Towers T, Presta L, Ravetch J (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446 (Pubitemid 30208162)
25. Manning E, Ullman J, Leatherman J, Asquith J, Hansen T et al (2007) A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 13:3951-3959 (Pubitemid 47037603)
26. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 50:5209-5218 (Pubitemid 29503984)
27. Gabrilovich D, Ishida T, Nadaf S, Ohm J, Carbone D (1999) Antibodies to vascular endothelial growth factor enhance the eYcacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5:2963-2970 (Pubitemid 29493976)
28. Ozao-Choy J, Ma G, Kao J, Wang G, Meseck M et al (2009) The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune- based cancer therapies. Cancer Res 69:2514-2522
29. Edwards JP, Emens LA (2010) The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE in murine macrophages. Int Immunopharmacol 10:1220- 1228
30. Boni A, Cogdill A, Dang P, Udayakumar D, Njauw C et al (2010) Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without aVecting lymphocyte function. Cancer Res 70:5213-5219